Egypt: EIPICO's consolidated net profits fall 30% YoY in 9 months
Detailed summary
Egyptian International Pharmaceutical Industries Company (EIPICO) posted a 30.14% year-on-year (YoY) decline in consolidated net profits attributable to the holding company for…
Arab Finance: Egyptian International Pharmaceutical Industries Company (EIPICO) posted a 30.14% year-on-year (YoY) decline in consolidated net profits attributable to the holding company for the first nine months of 2026, according to financial statements filed to the Egyptian Exchange (EGX) on November 15.
The company's consolidated net profit excluding minority interest amounted to EGP 792.973 million, down from EGP 1.135 billion in the same period a year earlier.
Consolidated net revenue rose 3.22% YoY to EGP 7.389 billion in the January-September period of 2026, compared to EGP 7.158 billion a year earlier.
Meanwhile, the company recorded a 39.33% YoY decline in standalone net profit after tax to EGP 535.659 million, down from EGP 882.850 million in the corresponding period of 2025.
Founded in 1980, the pharmaceutical company currently exports to over 65 countries worldwide, including European, African, Asian, Latin American, and Commonwealth countries.
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
Opening of the article, excerpted from Zawya. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.zawya.com)
